

Supporting Information

MuSPAD sampling/survey period:

The blood sampling period took place from June 6th, 2022 to July 3rd, 2022. We chose three existing MuSPAD study sites: City Region Aachen (around 560,000 inhabitants), Magdeburg (around 236,000 inhabitants) and Hannover (around 536,000 inhabitants). From June 2022 on, we send out our online and paper-based survey to all established MuSPAD participants (Freiburg, Reutlingen, Chemnitz, Greifswald, Magdeburg, Hannover, Aachen, and Osnabrück).

Lab analysis:

The serum samples obtained were analyzed centrally at the Institutes of Clinical Chemistry and Laboratory Medicine in Oldenburg and Greifswald. The Elecsys® Anti-SARS-CoV-2 S and Elecsys® Anti-SARS-CoV-2 NC (both Roche Diagnostics, Mannheim, Germany) were used for the determination of the quantitative antibody response against the S and N antigen of SARS-CoV-2. For Nucleocapsid (NC) protein we used ≥ 0.8 BAU/ml cut-offs for seropositivity. We also performed SARS-CoV-2 specific interferon-gamma release response (IGRA) using SARS-CoV-2 LIASION QuantiFERON-TB Gold Plus Qiagen®. For the blood collection, we used Lithium-Heparin Monovette and transferred them into specialized QFT-Plus Blood Collection with 24 h. We incubated the samples for 16 to 24 hours at 37°C, centrifuged the tubes at 2000 to 3000 RZB (g) for 15 minutes. Subsequently we detected released IFN γ in harvested plasma by ELISA.

For the neutralization assay, we investigate the activity of heat-inactivated (56°C) serum against lentivirus (HIV)-based pseudoviruses. Our assay is a further development of the protocol of Crawford et al.²⁵. In the methodology used, it was first described by us in the paper by Vanshylla et al.²⁴. For our serum samples, the 50% inhibitory serum dilution (ID50) was tested against pseudoviruses with the spike protein of the Wu01 variant and the BA.4/5 variant. Samples were tested in a 1:3 dilution series at dilutions ranging from 1:10 to 1:21,870 - this is within the quantification range of the assay.

Supplementary Table S1: Protection against severe course of disease and infection in adults for different combinations of vaccination and infection with the Omicron variant¹

| Exposures | VE² | VE in studies without information on follow-up | VE 0-13 days | VE 14-90 days | VE 91-180 days | VE >180 days |
|------------------|---------------------------------------|---|---------------------|----------------------|-----------------------|------------------------|
| 4 Exposures | Infection ³ | 46-96% (n=6) | 36% (n=1) | 88-98% (n=2) | 72-96% (n=2) | 82% (n=1) |
| | Severe course of disease ⁴ | 68-97% (n=4) | | | | |
| | Death | 81% (n=1) | | | | |
| 3 Exposures | Infection ³ | 35-78% (n=13) | 18-69% (n=8) | 32-89% (n=14) | 5-96% (n=10) | 34-68% (n=3) |
| | Severe course of disease ⁴ | 34-99%, AZ 30% (n=9) | 65-95% (n=3) | 59-97% (n=10) | 52-95% (n=10) | 65% (n=1) |
| | Death | 66-98% (n=2) | 71-86% (n=1) | 82-86% (n=2) | 87% (n=1) | 77% (n=1) |
| 1-2 Exposures | Infection ³ | -6-90% (n=17) | 10-23% (n=2) | 12-82% (n=16) | 3-70% (n=15) | -13-56% (n=9) |
| | Severe course of disease ⁴ | 41-97% (n=10) | 28-46% (n=1) | 42-96% (n=10) | 22-91% (n=14) | 12-88% (n=6) |
| | Death | 66-90% (n=3) | -9-29% (n=2) | 60-62% (n=2) | 57-70% (n=1) | 49-57% (n=2) |

¹ Interims analysis (see <https://zenodo.org/record/7177592#.Y4okYnbMI2w>) based on 27 identified studies from View hub on 9/27/2022; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, World Health Organization, Coalition for Epidemic Preparedness Innovations. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review: Weekly Summary Tables. Updated September 22, 2022. Available from: URL: https://view-hub.org/sites/default/files/2022-09/COVID19_Vaccine_Effectiveness_Transmission_Studies_Summary_Tables_20220922.pdf.

² VE Vaccine effectiveness (reference: no vaccination, infection, or antibodies); range of point estimates of the included studies

³ Definitions included every, symptomatic, or documented infection

⁴ Definitions included hospitalization, admission on intensive care unit, and/or death

Supplementary Table S2: Combined endpoint in those with and without IGRA Age distribution of the MuSPAD participants with blood samples grouped by combined endpoints including IGRA test results

| Age groups in years | 18-34 n (%) | 35-49 n (%) | 50-64 n (%) | 65-79 n (%) | 80+ n (%) | Overall n (%) ¹ |
|---|-----------------------|-------------------------|------------------------|------------------------|-----------------------|-------------------------------|
| Combined endpoints in those with blood sampling n=2898 | | | | | | |
| 3 exposures + one in 2022 | 85 (31.1%) | 168 (35.1%) | 297 (26.0%) | 372 (42.7%) | 69 (51.5%) | 991 (34.2%) |
| 3 exposures | 170 (62.3%) | 275 (57.5%) | 786 (68.9%) | 481 (55.2%) | 63 (47.0%) | 1775 (61.2%) |
| 1-3 exposures, or no immune correlates | 18 (6.6%) | 34 (7.1%) | 51 (4.5%) | 15 (1.7%) | 1 (0.7%) | 119 (4.1%) |
| 0 exposures, no immune correlates | 0 (0%) | 1 (0.2%) | 7 (0.6%) | 4 (0.5%) | 1 (0.7%) | 13 (0.4%) |
| Total | 273 | 478 | 1141 | 872 | 134 | 2898 |
| Combined endpoint including IGRA result in those with IGRA* sampling n=973^{1,2} | | | | | | |
| 3 exposures + one in 2022 (n; %IGRA negative) | 33; 27.0% (5; 2%) | 58; 31.2%; (5; 8.6%) | 60; 19.5% (9; 15.0%) | 101; 36.9% (31; 30.7%) | 38; 23.6% (21; 55.3%) | 290, 29.8% (71; 24.5%) |
| 3 exposures (n; % IGRA negative) | 81; 66.4% (21; 25.9%) | 103; 55.4%; (24; 23.3%) | 224; 73.0% (68; 30.4%) | 168; 61.3% (90; 53.6%) | 45; 28.0% (25; 55.6%) | 621; 63.8% (228; 36.7%) |
| 1-3 exposures, or no immune correlates (n; % IGRA negative) | 8; 6.6% (6; 75.0%) | 24; 12.9% (12; 50.0%) | 21; 6.8% (8; 38.1%) | 3; 1.1% (1; 33.3%) | 0 | 56; 5.8% (27; 48.2%) |
| 0 exposures, no immune correlates (n; % IGRA negative) | 0 | 1; 0.5% (1; 100%) | 2; 0.7% (2; 100%) | 2; 0.7% (2; 100%) | 1; 0.6% (100%) | 6; 0.6% (6; 100%) |
| Total | 122 | 186 | 307 | 274 | 84 | 973 |


*IGRA= interferon-gamma release response; ¹43 participants did not specify age; ²62 participants did not indicate a combined endpoint

Supplementary Table S3: Parametrization of the combined endpoints with and without humoral immune correlations as well as positive or negative IGRA based on literature synthesis


| Groups of combined endpoints | Vaccination/Infection/Immunity | Parametrization of models | Protection vs symptomatic infection for fully protected | Protection vs hospitalization for fully protected | Protection vs ICU* for fully protected |
|--|--|--|---|---|--|
| Group I 3 + 1 exposure in 2022 | 3 exposures (vaccination or infection) with humoral immune correlates* + one infection/vaccination in 2022 | Probably high protection vs severe course of disease Some protection vs infection | 40-60% | 70-90% | 70-90% |
| Group II 3 exposures | 3 exposures (vaccination or infection) with humoral immune correlates* | Moderate protection vs severe course of disease Some protection vs infection | 10-30% | 50-70% | 50-70% |
| Group III 1-3 exposures or no immune correlates | 3 or more exposures without immune correlate, 1-2 exposures with or without immune correlate or 0 exposures with at least 1 positive humoral immune correlate* | Some protection vs severe course of disease Little protection vs infection | 0 | 20-40% | 20-40% |

*ICU= intensive care unit

Supplementary Figure S1: Scatterplot of correlation between anti-S by two variants Wu01 and BA.5 (A, B) and anti-NC antibody titers (C, D) based on ELISA test and neutralization



Supplementary Figure S2: Boxplot of BA.5 neutralizing antibody response by time since last SARS CoV-2 vaccination **(a)** and last SARS-CoV-2 infection **(b)** stratified by IGRA



Supplementary Figure 3: Weekly number of COVID 19 cases hospitalized, cumulated over all age groups in Germany
(https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/Klinische_Aspekte.xlsx?__blob=publicationFile)

